Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Overview of attention for article published in Blood Cancer Journal, February 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 1,168)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 51 news outlets
twitter: 13 tweeters

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 50 Mendeley

Summary News Twitter Wikipedia Dimensions citations

So far, Altmetric has seen 61 news stories from 51 outlets.

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Biz Wire Express, 26 May 2022

GlobeNewswire 2022-05-26 Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) poster…

News story from Finanz Nachrichten on Thursday 26 May 2022

Finanz Nachrichten, 26 May 2022

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Wsil3abc, 26 May 2022

- Genmab A/S(Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational medicines in the company’s…

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Wall Street Online Denmark, 26 May 2022

Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody-CD3xCD20) poster presentations highlighting data…

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MarketScreener, 26 May 2022

(Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational medicines in the company’s pipeline…

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire, 26 May 2022

Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and…

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Yahoo! Finance USA, 26 May 2022

Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data…

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Biospace, 26 May 2022

Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and…

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire, 26 May 2022

Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Stockwatch, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

ProfitQuotes.com, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Ticker Tech, 12 May 2022

NORTH CHICAGO, Ill., May 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer…

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

gurufocus, 12 May 2022

Genmab+A%2FS (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Wave 3 News, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WBTV, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

News story from WHSV3 on Thursday 12 May 2022

WHSV3, 12 May 2022

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Benzinga, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

14 News, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WILX 10, 12 May 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WWSB, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WSAW-TV, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WECT News 6, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

KPLC 7 News, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Fox 8 WVUE, 12 May 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WMBF News, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

News story from wrdw on Thursday 12 May 2022

wrdw, 12 May 2022

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

KEYC News 12, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

NBC12, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WTVM, 12 May 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

South Carolina News Now, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WCAX, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WFLX Fox 29, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Hawaii News Now, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WAFB 9, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

KSLA News 12, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

News Channel 10, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WFMZ-TV 69, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

KCBD, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Fox 19, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WALB, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Yahoo! Finance USA, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

WDAM - TV, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

KAIT-TV, 12 May 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

PR Newswire, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Morning Star, 12 May 2022

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses PR Newswire NORTH CHICAGO, Ill.

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

Knoe News 8, 12 May 2022

AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update…

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

KLTV, 12 May 2022

A five-year update from the CLL14 Phase 3 VENCLYXTO®/VENCLEXTA® (venetoclax) and obinutuzumab in previously untreated patients…

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Spoke, 12 May 2022

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress Multiple…

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

Biz Wire Express, 12 May 2022

GlobeNewswire 2022-05-12 Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will…

News story from Finanz Nachrichten on Thursday 12 May 2022

Finanz Nachrichten, 12 May 2022

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

The Daily Times, 12 May 2022

- Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an…

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Bakersfield, 12 May 2022

- Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an…

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

MarketScreener, 12 May 2022

Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Morning Star, 12 May 2022

Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a…

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

Yahoo! Finance USA, 12 May 2022

Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

Okonomisk Ugebrev, 12 May 2022

Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

Yahoo! Finance USA, 12 May 2022

being held in Vienna, Austria, and virtually, June 9-12. The presentations will include data from various clinical trials…

Genmab Announces Multiple Abstracts To Be Presented At The European Hematology Association (EHA) Annual Congress

The Street, 12 May 2022

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational…

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Business Wire, 12 May 2022

Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a…

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

GlobeNewswire, 12 May 2022

Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Biospace, 12 May 2022

Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a…